{"title":"奥美沙坦治疗心血管疾病的最新进展。","authors":"Shin-ichiro Miura, Keijiro Saku","doi":"10.3109/10641963.2013.846363","DOIUrl":null,"url":null,"abstract":"<p><p>Angiotensin II (Ang II) evokes inflammatory responses and plays a central role in atherosclerosis mediated by Ang II type 1 (AT1) receptor. AT1 receptor blockers (ARBs) prevent the diverse effects of Ang II. Unique molecule-specific, or off-target effects of ARBs are due to their slightly different structures, although all ARBs have common, or class, effects. In nonsignificant coronary stenotic lesions, it is important that we use aggressive medical treatments using ARBs in addition to statins and oral hypoglycemic agents, to induce the regression and stabilization of coronary plaque. This review focuses on current evidence regarding the molecule-specific effects of ARB olmesartan to prevent the increase in coronary atheroma volume.</p>","PeriodicalId":286988,"journal":{"name":"Clinical and Experimental Hypertension (New York, N.y. : 1993)","volume":" ","pages":"441-6"},"PeriodicalIF":0.0000,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3109/10641963.2013.846363","citationCount":"7","resultStr":"{\"title\":\"Recent progress in the treatment of cardiovascular disease using olmesartan.\",\"authors\":\"Shin-ichiro Miura, Keijiro Saku\",\"doi\":\"10.3109/10641963.2013.846363\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Angiotensin II (Ang II) evokes inflammatory responses and plays a central role in atherosclerosis mediated by Ang II type 1 (AT1) receptor. AT1 receptor blockers (ARBs) prevent the diverse effects of Ang II. Unique molecule-specific, or off-target effects of ARBs are due to their slightly different structures, although all ARBs have common, or class, effects. In nonsignificant coronary stenotic lesions, it is important that we use aggressive medical treatments using ARBs in addition to statins and oral hypoglycemic agents, to induce the regression and stabilization of coronary plaque. This review focuses on current evidence regarding the molecule-specific effects of ARB olmesartan to prevent the increase in coronary atheroma volume.</p>\",\"PeriodicalId\":286988,\"journal\":{\"name\":\"Clinical and Experimental Hypertension (New York, N.y. : 1993)\",\"volume\":\" \",\"pages\":\"441-6\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2014-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.3109/10641963.2013.846363\",\"citationCount\":\"7\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical and Experimental Hypertension (New York, N.y. : 1993)\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3109/10641963.2013.846363\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2013/10/28 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Experimental Hypertension (New York, N.y. : 1993)","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3109/10641963.2013.846363","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2013/10/28 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 7
摘要
血管紧张素II (Ang II)引起炎症反应，并在由Ang II 1型(AT1)受体介导的动脉粥样硬化中起核心作用。AT1受体阻滞剂(ARBs)可防止Ang II的多种作用。尽管所有的arb都有共同的或同类的作用，但由于它们的结构略有不同，arb具有独特的分子特异性或脱靶效应。在不明显的冠状动脉狭窄病变中，除了他汀类药物和口服降糖药外，我们还需要积极的药物治疗，如arb，以诱导冠状动脉斑块的消退和稳定。本文综述了ARB奥美沙坦预防冠状动脉粥样硬化体积增加的分子特异性作用的最新证据。
Recent progress in the treatment of cardiovascular disease using olmesartan.
Angiotensin II (Ang II) evokes inflammatory responses and plays a central role in atherosclerosis mediated by Ang II type 1 (AT1) receptor. AT1 receptor blockers (ARBs) prevent the diverse effects of Ang II. Unique molecule-specific, or off-target effects of ARBs are due to their slightly different structures, although all ARBs have common, or class, effects. In nonsignificant coronary stenotic lesions, it is important that we use aggressive medical treatments using ARBs in addition to statins and oral hypoglycemic agents, to induce the regression and stabilization of coronary plaque. This review focuses on current evidence regarding the molecule-specific effects of ARB olmesartan to prevent the increase in coronary atheroma volume.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
